why does nobody talk about cagrilintide
why does nobody talk about cagrilintide — that is what I am asking, and I have already read the wiki twice.
The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised.
Kept a log purely because so few people are logging this one. It is one person and it is not data.
Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.
If two or three other people have done the same thing we might actually learn something. Alone it is an anecdote.
best — the order this archive was captured in
Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.
Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.
Small fix — amylin analogue, not a GLP-1 analogue.
freya_baptista is right that the evidence base here is thin. Conclusions should be held loosely.
Disagree — you are quoting a combination arm as though it were monotherapy. Those are different results.
nothing here is approved as a standalone product and research material is not for human use
Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.
Correction: that is the combination programme, not the monotherapy readout.
Agreed, and the combination arms are where the interesting numbers actually live.
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes.
Adding the standing caveat — nothing here is approved standalone and research material is not for human use.
amylin analogue, different receptor family, different story
do not assume the dosing intuitions from the GLP-1 boards transfer
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.
satiety signalling rather than incretin signalling
Left up. Thin evidence base, honestly labelled, which is the standard here.
Sent a vial to VendorInvestigate because there was almost nothing on file for this compound. 99.4% against a claimed 98.5%, and I posted it because the log needs entries.
- 1Amylin is co-secreted with insulin and acts on satiety and gastric emptying…11 comments in this branch · started by u/nadia_bakker